How long until widespread AI use comes to health systems?

The answer to this question depends, not only on how well AI tools work, but also on how AI technologies are regulated by the FDA. Scott Gottlieb has some thoughts on preferred regulatory approaches in his recent article in JAMA Health Forum. Artificial intelligence tools with advanced analytical capabilities used in clinical practice, especially tools…

Read More

Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots

The Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs. The antibody offers the potential to prevent blood clots without the bleeding risks associated with currently available anticoagulants. The post Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots appeared first on MedCity News.

Read More